Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Chronic GVHD Incidence and Risk Factors

September 4th 2023

Dr Gooptu discusses the incidence of chronic GVHD and ruminates on how a patient’s medical history may impact their chronic GVHD risk.

Role of BTK Inhibitors in Relapsed/Refractory Follicular Lymphoma

September 1st 2023

A brief review of BTK inhibitor therapy and its potential role within the relapsed/refractory follicular lymphoma treatment landscape.

Patient Scenario 1: An 83 -Year-Old With Relapsed/Refractory FL

September 1st 2023

Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

August 31st 2023

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Acute Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Following the ASCO 2023 and EHA 2023 Annual Meetings, experts discuss important updates in acute myeloid leukemia.

Acute Lymphoblastic Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Shared insight from key opinion leaders on clinical trial data in acute lymphoblastic leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

Chronic Myeloid Leukemia: Trial Data From the ASCO and EHA 2023 Annual Meetings

August 31st 2023

Expert perspectives on key data in chronic myeloid leukemia from the ASCO 2023 and EHA 2023 Annual Meetings.

FDA Grants Orphan Drug Designation to Bexmarilimab for AML

August 29th 2023

The FDA has granted an orphan drug designation to bexmarilimab for the treatment of patients with acute myeloid leukemia.

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29th 2023

The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.

Advancing the Treatment Landscape in Philadelphia-Positive ALL

August 29th 2023

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

Ph+ ALL Management Updates: Expert Insights

August 29th 2023

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Evolving Treatment Landscape of Myelofibrosis

August 29th 2023

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

August 29th 2023

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis stimulating agent (ESA) use in adult patients with very low– to intermediate-risk myelodysplastic syndrome (MDS) who may require regular red blood cell (RBC) transfusions.

Dr Islam on Novel Explorations of BTK Inhibitors in MCL and CLL

August 28th 2023

Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Komrokji Examines Differences Between the WHO and ICC MDS Criteria

August 28th 2023

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

Clinical Scenario: Chronic Graft Versus Host Disease

August 28th 2023

Signs and symptoms of chronic GVHD are explained through the lens of the clinical scenario.

Education and Resources for Patients with GVHD

August 28th 2023

The panel highlights the importance of a multidisciplinary approach and best practices in education for patients with GVHD.

Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

August 24th 2023

Sovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopenia in China.

Ponatinib Plus Low-Dose Chemotherapy Improves MRD– CR Rates in Newly Diagnosed Ph+ ALL

August 24th 2023

Elias Jabbour, MD, outlines additional findings from PhALLCON and their clinical implications for patients with Philadelphia chromosome-positive ALL